These phenotypic characteristics have been shown to impact responses to small-molecular inhibitors (50) and could render these lymphomas sensitive to the anti-CD79B antibody–drug conjugate polatuzumab vedotin with promising efficacy especially in the ABC DLBCLs (51, 52). Here, CD79B is linked to lymphoma.